NKGen Biotech Administers First Dose of Troculeucel to Alzheimers Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy
July 10, 2025 16:30 ET Â | Source: NKGen Biotech, Inc. SANTA ANA,…
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessas Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
July 04, 2025 03:00 ET Â | Source: Nxera Pharma Tokyo, Japan and…
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET Â | Source: Instil Bio US phase 1…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
July 02, 2025 03:00 ET Â | Source: Belite Bio, Inc -Â 500…
Bavarian Nordic Announces Sale of Priority Review Voucher for USD 160 Million
COPENHAGEN, Denmark, June 18, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced…
ArkBio’s New Drug Application for ADHD Therapeutic Azstarys Accepted and Granted Priority Review by China NMPA
SHANGHAI, June 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio")…
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the…
Continuity Biosciences Acquires Focal Medical to Advance Targeted Drug Delivery for Pancreatic Cancer
BRADENTON, Fla., June 4, 2025 /PRNewswire/ -- Continuity Biosciences, LLC, a developer…
Press Release: Rilzabrutinib granted orphan drug designation in the US for sickle cell disease
Rilzabrutinib granted orphan drug designation in the US for sickle cell disease…